Navigation Links
VEGF Inhibition: Therapy-Indicating and Prognostic Biomarkers, 2013
Date:2/5/2013

NEW YORK, Feb. 5, 2013 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

 

VEGF Inhibition: Therapy-Indicating and Prognostic Biomarkers, 2013

http://www.reportlinker.com/p0656768/VEGF-Inhibition-Therapy-Indicating-and-Prognostic-Biomarkers-2013.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Genomics

 

Vascular Endothelial Growth Factor (VEGF), which plays an important role in angiogenesis, has been extensively studied and over-expression is seen in many cancers. Today, VEGF is targeted using antibodies and tyrosine kinase inhibitors, and antiangiogenic therapy is a standard treatment for many cancers, including colorectal and non-small cell lung cancer.

 

While VEGF inhibitors such as bevacizumab (Avastin®) provide valuable treatment options, these benefits are not seen in all patients and cancer types. Today, there is an urgent need for predictive biomarkers to enable those patients most likely to benefit from VEGF inhibition, to be identified. This report provides a review of findings to date on biomarkers associated with the use bevacizumab (Avastin®); both therapy-indicating and prognostic.

 

The identification of therapy-indicating and prognostic biomarkers relating to antiangiogenic therapy is in its early stages, however important advances have been made. This report identifies the latest findings on ten different cancers and includes an evaluation of candidate biomarkers as a basis for interpreting patient outcomes according to RECIST criteria, and evaluates existing bevacizumab-containing treatments and drug combinations.

 

Key content:

• A comprehensive review of clinical studies that have identified biomarkers that are either therapy-indicating in respect of bevacizumab (Avastin®) or indicative of patient prognosis

• Biomarkers identified or further evaluated in the last five years, up until January 2013. From a background of extensive research on bevacizumab (Avastin®) and VEGF-related biomarkers, the most important findings have been identified for their significance and value to patients and in designing clinical trials

• Covering more than ten cancers including colorectal, ovarian, renal, breast, pancreatic, prostate, lung and liver cancers

• Findings based on clinical trial findings including patient numbers, statistics and RECIST criteria

• Studies indicate drug type associations together with comparative therapies

• Descriptions and explanation of all biomarkers identified (proteins, genotypes, imaging etc)

• Biomarker associations are categorised according to three broad criteria, namely "positive-therapy-indicating" (response, improved response, improved outcome or prognosis), "non-therapy-indicating" (no differences in tumour response, outcome or prognosis) and "negative-therapy-indicating" (adverse events, poor outcome or prognosis).

 

 

 

Executive Summary

 

Chapter 1: Background (p.18)

 

1.1 VEGF Inhibition

1.2 Bevacizumab

1.3 Biomarkers

1.4 This Report

 

Chapter 2 Colorectal Cancer: Candidate Biomarkers identified in Patients receiving Bevacizumab-containing Therapies (p. 22)

 

Summary

2.1 Introduction

2.2 Glycoprotein

2.3 Protein

2.4 Protein

2.5 Cells

2.6 Genetic

2.7 Physical

2.8 Genetic

2.9 Protein

2.10 Proteins

2.11 Proteins and Genetic

2.12 Image

2.13 Proteins

2.14 Protein

 

Chapter 3 Breast Cancer: Candidate Biomarkers identified in Patients receiving Bevacizumab-containing Therapies (p.42)

 

Summary

3.1 Introduction

3.2 Protein

3.3 Protein

3.4 Protein

3.5 Protein

3.6 Protein

3.7 Genetic

3.8 Protein

 

Chapter 4 Renal Cancer: Candidate Biomarkers identified in Patients receiving Bevacizumab-containing Therapies (p.50)

 

Summary

4.1 Introduction

4.2 Image

4.3 Protein

4.4 Physical

4.5 Protein

4.6 Body Characteristic

 

Chapter 5 Ovarian Cancer: Candidate Biomarkers identified in Patients receiving Bevacizumab-containing Therapies (p.55)

 

Summary

5.1 Introduction

5.2 Proteins

5.3 Proteins

5.4 Proteins

5.5 Proteins

 

Chapter 6 Lung Cancer: Candidate Biomarkers identified in Patients receiving Bevacizumab-containing Therapies (p.60)

 

Summary

6.1 Introduction

6.2 Physical Parameter

6.3 Protein

6.4 Genetic

6.5 Protein

 

Chapter 7 Liver Cancer: Candidate Biomarkers identified in Patients receiving Bevacizumab-containing Therapies (p.65)

 

Summary

7.1 Introduction

7.2 Protein

7.3 Image

 

Chapter 8 Other Cancers: Candidate Biomarkers identified in Patients receiving Bevacizumab-containing Therapies (p.71)

 

Summary

8.1 Introduction

8.2 Proteins

8.3 Proteins

8.4 Protein

8.5 Protein

8.6 Physical

8.7 Physical

8.8 Physical

 

Chapter 9: Discussion (p.80)

 

9.1 Overview

9.2 Colorectal Cancer

9.3 Breast Cancer:

9.4 Renal Cancer:

9.5 Ovarian Cancer

9.6 Lung Cancer

9.7 Liver Cancer

9.8 Other Cancers

9.9 Conclusions

 

 

 

Tables

 

Table 2.1 Candidates biomarkers identified in colorectal cancer patients receiving bevacizumab-containing therapies (cancer, biomarker, biomarker type, drug therapies)

Table 3.1 Candidates biomarkers identified in breast cancer patients receiving bevacizumab-containing therapies (cancer, biomarker, biomarker type, drug therapies)

Table 4.1 Candidates biomarkers identified in renal cancer patients receiving bevacizumab-containing therapies (cancer, biomarker, biomarker type, drug therapies)

Table 5.1 Candidates biomarkers identified in ovarian cancer patients receiving bevacizumab-containing therapies (cancer, biomarker, biomarker type, drug therapies)

Table 6.1 Candidates biomarkers identified in lung cancer patients receiving bevacizumab-containing therapies (cancer, biomarker, biomarker type, drug therapies)

Table 7.1 Candidates biomarkers identified in liver cancer patients receiving bevacizumab-containing therapies (cancer, biomarker, biomarker type, drug therapies)

Table 8.1 Candidates biomarkers identified in other cancer patients receiving bevacizumab-containing therapies (cancer, biomarker, biomarker type, drug therapies)

Table 9.1 Protein candidate biomarkers identified in cancer patients receiving bevacizumab-containing therapies (cancer, biomarker, biomarker type, drug therapies)

Table 9.2 Genetic candidate biomarkers identified in cancer patients receiving bevacizumab-containing therapies (cancer, biomarker, biomarker type, drug therapies)

Table 9.3 Image-based candidate biomarkers identified in cancer patients receiving bevacizumab-containing therapies (cancer, biomarker, biomarker type, drug therapies)

Table 9.4 Other candidate biomarkers identified in cancer patients receiving bevacizumab-containing therapies (cancer, biomarker, biomarker type, drug therapies)

 

 

 

Figures

 

Figure 9.1 Candidate biomarkers types identified in cancer patients receiving bevacizumab-containing therapies

Figure 9.2 Cancer types evaluated for biomarkers identified in cancer patients receiving bevacizumab-containing therapies

Figure 9.3 Author countries (identified in this report) of cancers evaluated for biomarkers identified in cancer patients receiving bevacizumab-containing therapies

 

 

 

To order this report:

Genomics Industry: VEGF Inhibition: Therapy-Indicating and Prognostic Biomarkers, 2013

 

Nicolas Bombourg
Reportlinker
Email: nicolasbombourg@reportlinker.com
US: (805)652-2626
Intl: +1 805-652-2626

 


'/>"/>
SOURCE Reportlinker
Copyright©2012 PR Newswire.
All rights reserved

Related biology news :

1. Study confirms prognostic value of new IASLC/ATS/ERS adenocarcinoma sub-classification
2. Game changing diagnostic & prognostic prostate cancer genetic tests revealed by Jefferson
3. EGFR mutation not prognostic factor in non-small cell lung cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/19/2017)... PORTLAND, Oregon and PUNE, India , January 19, ... Market Research, titled, "Global Biometric Sensor Market, Opportunities and Forecast, 2014 - ... 2022, growing at a CAGR of 9.6% from 2016 to 2022. In 2015, ... share owing to high-level security for both public and private sectors. ... ...
(Date:1/18/2017)... MINNETONKA, Minn. , Jan. 18, 2017 /PRNewswire/ ... eClinical technology company that supports the entire spectrum ... 2016 has been another record-breaking year for the ... and market interest in MedNet,s eClinical products and ... to the tremendous marketplace success of ...
(Date:1/12/2017)... NEW YORK , Jan. 12, 2017  New research ... around the office of the future.  1,000 participants were simply ... last three months which we may consider standard issue.  Insights ... office of 2017 were also gathered from futurists and industry ... and Dr. James Canton .  Some ...
Breaking Biology News(10 mins):
(Date:2/20/2017)... ORLANDO, Fla. , Feb. 20, 2017 /PRNewswire/ ... (HIMSS) conference in Orlando , ... new offerings, collaborators and clients. IBM Chairman, President ... the HIMSS17 opening keynote address today from 8:30-10 ... www.ibm.com/watson/health , and ibm.com/industries/healthcare. Her remarks examine ...
(Date:2/18/2017)... MONTREAL , February 18, 2017 ... von intrazellulären Zytokinen bei adoptiven Zelltherapie-Studien, Poster legt metaproteomische ... ... Biosciences Inc. heute bekanntgab, wird Dr. Yoav Peretz ... Methoden in der Entwicklung von Assays zum Nachweis intrazellulärer ...
(Date:2/18/2017)... Research and Markets has announced the addition of the ... offering. ... report provides separate comprehensive analytics for the US, Japan ... Annual estimates and forecasts are provided for the period 2015 through ... Market data and analytics are derived from primary and secondary research. ...
(Date:2/17/2017)... 17, 2017  If only one in every ... mutation-conferring resistance to chemotherapy, thousands of cancer cells ... focused on finding these mutations in ever-smaller subpopulations ... tumor DNA in blood — to guide treatment ... Unfortunately, however, detecting these genetic anomalies may ...
Breaking Biology Technology: